Insider Buying: Orthofix Medical (NASDAQ:OFIX) Major Shareholder Acquires $365,400.00 in Stock

Key Points

• Engine Capital Management, LP bought 30,000 shares of Orthofix on May 7 at $12.18, bringing its direct stake to 3,848,573 shares (≈$46.9M), a 0.79% increase.
• The firm completed multiple recent purchases (May 5–7 and Feb 24–25), spending roughly $4.0 million on OFIX stock across those transactions.
• Orthofix reported Q results with EPS of -$0.52 (beat estimates) and revenue of $196.7M; the stock trades near $12.07, carries a market cap of ~$484.5M, and has a consensus analyst rating of “Hold” with an average target of $17.25.

Orthofix Medical Inc. (NASDAQ:OFIX - Get Free Report) major shareholder Engine Capital Management, Lp purchased 30,000 shares of Orthofix Medical stock in a transaction that occurred on Thursday, May 7th. The shares were bought at an average cost of $12.18 per share, with a total value of $365,400.00. Following the completion of the transaction, the insider directly owned 3,848,573 shares of the company's stock, valued at approximately $46,875,619.14. The trade was a 0.79% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Major shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.

Engine Capital Management, Lp also recently made the following trade(s):

• On Wednesday, May 6th, Engine Capital Management, Lp purchased 41,946 shares of Orthofix Medical stock. The shares were acquired at an average cost of $12.23 per share, for a total transaction of $512,999.58.
• On Tuesday, May 5th, Engine Capital Management, Lp purchased 112,950 shares of Orthofix Medical stock. The shares were acquired at an average cost of $11.99 per share, for a total transaction of $1,354,270.50.
• On Wednesday, February 25th, Engine Capital Management, Lp acquired 13,061 shares of Orthofix Medical stock. The shares were purchased at an average price of $12.96 per share, with a total value of $169,270.56.
• On Tuesday, February 24th, Engine Capital Management, Lp acquired 124,797 shares of Orthofix Medical stock. The shares were purchased at an average price of $12.55 per share, with a total value of $1,566,202.35.

Orthofix Medical Price Performance

Shares of OFIX stock traded down $0.12 during trading on Thursday, hitting $12.07. The company had a trading volume of 446,930 shares, compared to its average volume of 268,323. The stock's 50-day moving average price is $12.21 and its 200 day moving average price is $13.91. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.43 and a current ratio of 2.87. Orthofix Medical Inc. has a one year low of $10.24 and a one year high of $16.99. The firm has a market capitalization of $484.49 million, a P/E ratio of -7.99 and a beta of 0.79.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) last released its earnings results on Tuesday, May 5th. The medical device company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.16. Orthofix Medical had a negative return on equity of 13.44% and a negative net margin of 7.27%.The firm had revenue of $196.71 million during the quarter, compared to analysts' expectations of $196.40 million. Equities analysts expect that Orthofix Medical Inc. will post -1.57 EPS for the current fiscal year.

Institutional Trading of Orthofix Medical

A number of large investors have recently bought and sold shares of the business. Juniper Investment Company LLC lifted its position in Orthofix Medical by 15.3% in the 3rd quarter. Juniper Investment Company LLC now owns 2,847,055 shares of the medical device company's stock valued at $41,681,000 after acquiring an additional 377,729 shares in the last quarter. Tudor Investment Corp ET AL lifted its position in shares of Orthofix Medical by 268.8% during the 3rd quarter. Tudor Investment Corp ET AL now owns 217,044 shares of the medical device company's stock worth $3,178,000 after buying an additional 158,197 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Orthofix Medical by 33.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 258,035 shares of the medical device company's stock worth $3,778,000 after buying an additional 64,486 shares in the last quarter. Palumbo Wealth Management LLC bought a new position in shares of Orthofix Medical during the 3rd quarter worth approximately $629,000. Finally, Versor Investments LP lifted its position in shares of Orthofix Medical by 60.4% during the 3rd quarter. Versor Investments LP now owns 34,700 shares of the medical device company's stock worth $508,000 after buying an additional 13,067 shares in the last quarter. 89.76% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Barrington Research reiterated an "outperform" rating and issued a $17.00 price target on shares of Orthofix Medical in a research note on Friday, April 10th. TD Cowen assumed coverage on Orthofix Medical in a research note on Tuesday, January 27th. They issued a "hold" rating and a $14.00 price target for the company. Wall Street Zen cut Orthofix Medical from a "buy" rating to a "hold" rating in a research note on Saturday, May 2nd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Orthofix Medical in a research note on Tuesday, April 21st. Finally, Canaccord Genuity Group dropped their price target on Orthofix Medical from $24.00 to $20.00 and set a "buy" rating for the company in a research note on Thursday, February 26th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $17.25.

About Orthofix Medical

Orthofix Medical Inc NASDAQ: OFIX is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company's core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix's product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.